MT Newswires
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading
➖
AI Sentiment
Neutral
5/10
as of 12-12-2025 3:09pm EST
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.
| Founded: | 1992 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 18.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 78.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.48 - $3.44 | Next Earning Date: | 11-14-2025 |
| Revenue: | $61,555,000 | Revenue Growth: | 8.31% |
| Revenue Growth (this year): | 13.51% | Revenue Growth (next year): | 13.14% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
TRIB Breaking Stock News: Dive into TRIB Ticker-Specific Updates for Smart Investing
AI Sentiment
Neutral
5/10
AI Sentiment
Neutral
5/10
See how TRIB stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "TRIB Trinity Biotech plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.